Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Alflutop is an injectable chondroprotective drug derived from a bioactive concentrate of small marine fish. Its formulation contains mucopolysaccharides (notably chondroitin sulfate), amino acids, peptides, and minerals such as sodium, potassium, calcium, magnesium, iron, copper, and zinc. Alflutop acts by inhibiting hyaluronidase activity, thus protecting and stimulating the biosynthesis of hyaluronic acid, which is essential for joint fluid and cartilage integrity. The drug promotes tissue regeneration, reduces pain through an analgesic effect, and demonstrates anti-inflammatory activity. The primary indications are osteoarthritis (both primary and secondary forms), spondylosis, and osteochondrosis. It is reported to improve joint function, reduce pain, and retard disease progression in osteoarthritic patients. Alflutop is administered via intramuscular and intra-articular injections[1][3][5][6][7][8].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on alflutop.